Literature DB >> 22585683

Mucin as a therapeutic target in pseudomyxoma peritonei.

Haroon A Choudry1, Mark E O'Malley, Zong Sheng Guo, Herbert J Zeh, David L Bartlett.   

Abstract

Pseudomyxoma peritonei (PMP) is characterized by intraperitoneal dissemination of mucinous ascites. This malignancy frequently recurs despite aggressive locoregional therapies, demonstrates chemo-insensitivity and lacks targeted therapies. This review addresses some intriguing questions in PMP; what role does mucin play in this malignancy?; what genetic alterations and dysregulated signaling pathways lead to a putative goblet cell-lineage differentiation or mucin overexpression?; are targeted therapies against known transcriptional pathways for mucin production a novel therapeutic strategy in this malignancy?
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22585683     DOI： 10.1002/jso.23146

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN： 0022-4790            Impact factor:   3.454


  12 in total

Review 1.  Pseudomyxoma peritonei as an intractable disease and its preoperative assessment to help improve prognosis after surgery: A review of the literature.

Authors:  Yuesi Zhong; Meihai Deng; Ruiyun Xu; Norihiro Kokudo; Wei Tang
Journal:  Intractable Rare Dis Res       Date:  2012-08

2.  Improved chemosensitivity following mucolytic therapy in patient-derived models of mucinous appendix cancer.

Authors:  Ashok K Dilly; Brendon D Honick; Robin Frederick; Anuleka Elapavaluru; Sachin Velankar; Hima Makala; T Kevin Hitchens; Lesley M Foley; Jianxia Guo; Jan H Beumer; Lora Heather Rigatti; Yong J Lee; David L Bartlett; Haroon A Choudry
Journal:  Transl Res       Date:  2020-10-22       Impact factor: 7.012

3.  Targeting G-protein coupled receptor-related signaling pathway in a murine xenograft model of appendiceal pseudomyxoma peritonei.

Authors:  Ashok K Dilly; Brendon D Honick; Yong J Lee; Zong S Guo; Herbert J Zeh; David L Bartlett; Haroon A Choudry
Journal:  Oncotarget       Date:  2017-11-06

4.  Bilateral blockade of MEK- and PI3K-mediated pathways downstream of mutant KRAS as a treatment approach for peritoneal mucinous malignancies.

Authors:  Murali R Kuracha; Peter Thomas; Brian W Loggie; Venkatesh Govindarajan
Journal:  PLoS One       Date:  2017-06-22       Impact factor: 3.240

5.  A core microbiome associated with the peritoneal tumors of pseudomyxoma peritonei.

Authors:  Jeremy J Gilbreath; Cristina Semino-Mora; Christopher J Friedline; Hui Liu; Kip L Bodi; Thomas J McAvoy; Jennifer Francis; Carol Nieroda; Armando Sardi; Andre Dubois; David W Lazinski; Andrew Camilli; Traci L Testerman; D Scott Merrell
Journal:  Orphanet J Rare Dis       Date:  2013-07-12       Impact factor: 4.123

6.  Chronic Inflammation: Synergistic Interactions of Recruiting Macrophages (TAMs) and Eosinophils (Eos) with Host Mast Cells (MCs) and Tumorigenesis in CALTs. M-CSF, Suitable Biomarker for Cancer Diagnosis!

Authors:  Mahin Khatami
Journal:  Cancers (Basel)       Date:  2014-01-27       Impact factor: 6.639

Review 7.  Secreted mucins in pseudomyxoma peritonei: pathophysiological significance and potential therapeutic prospects.

Authors:  Afshin Amini; Samar Masoumi-Moghaddam; Anahid Ehteda; David Lawson Morris
Journal:  Orphanet J Rare Dis       Date:  2014-05-05       Impact factor: 4.123

8.  Patient-derived xenograft mouse models of pseudomyxoma peritonei recapitulate the human inflammatory tumor microenvironment.

Authors:  Murali R Kuracha; Peter Thomas; Brian W Loggie; Venkatesh Govindarajan
Journal:  Cancer Med       Date:  2016-02-02       Impact factor: 4.452

9.  Rational application of targeted therapeutics in mucinous colon/appendix cancers with positive predictive factors.

Authors:  Ashokkumar Dilly; Brendon D Honick; Yong J Lee; David L Bartlett; Haroon A Choudry
Journal:  Cancer Med       Date:  2020-01-20       Impact factor: 4.711

10.  Synergistic apoptosis following endoplasmic reticulum stress aggravation in mucinous colon cancer.

Authors:  Ashok K Dilly; Brendon D Honick; Yong J Lee; David L Bartlett; Haroon A Choudry
Journal:  Orphanet J Rare Dis       Date:  2020-08-18       Impact factor: 4.303
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.